Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/4/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 16/4/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 16/4/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +10.00% | +13.39% | +51.99% | +83.45% | 56.7B | |
| +0.80% | -5.70% | +23.89% | +62.65% | 51.97B | |
| -0.69% | -1.38% | -17.14% | -14.38% | 23.33B | |
| +0.36% | -5.28% | -11.34% | +348.52% | 21.34B | |
| +1.73% | -1.57% | +32.81% | -25.80% | 17.44B | |
| +4.29% | +1.67% | +201.24% | +344.48% | 14.77B | |
| +2.38% | -0.53% | +52.70% | +177.31% | 13.84B | |
| +3.61% | +3.22% | +437.78% | +179.76% | 12.12B | |
| +5.77% | -5.73% | +62.74% | +161.17% | 11.14B | |
| Average | +2.83% | -0.63% | +92.74% | +146.35% | 24.74B | |
| Weighted average by Cap. | +3.72% | +0.44% | +62.09% | +117.47% |
Employees
51
